What is B. Riley's Forecast for Journey Medical Q2 Earnings?

Key Points

• B. Riley has projected Journey Medical Corporation will report Q2 2025 earnings of ($0.06) per share, with full-year estimates for 2025 at ($0.25) EPS.
• In its last earnings release, Journey Medical reported a loss of $0.18 per share, exceeding the consensus estimate of ($0.24).
• The company has experienced shifts in analyst ratings, with Alliance Global Partners maintaining a "buy" rating, while Wall Street Zen downgraded it to a "hold".

Journey Medical Corporation (NASDAQ:DERM - Free Report) - Equities researchers at B. Riley issued their Q2 2025 earnings per share (EPS) estimates for shares of Journey Medical in a report issued on Wednesday, July 30th. B. Riley analyst M. Mamtani expects that the company will earn ($0.06) per share for the quarter. The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share. B. Riley also issued estimates for Journey Medical's Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at $0.45 EPS, FY2027 earnings at $1.33 EPS, FY2028 earnings at $2.17 EPS and FY2029 earnings at $0.85 EPS.

Journey Medical (NASDAQ:DERM - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.06. The business had revenue of $13.14 million during the quarter, compared to the consensus estimate of $12.05 million. Journey Medical had a negative return on equity of 52.03% and a negative net margin of 14.76%.

A number of other research analysts have also issued reports on DERM. Alliance Global Partners reiterated a "buy" rating on shares of Journey Medical in a research report on Thursday, May 15th. Wall Street Zen lowered Journey Medical from a "buy" rating to a "hold" rating in a research report on Sunday, July 6th.

Journey Medical Stock Performance

DERM stock traded down $0.04 during trading on Friday, reaching $7.11. 57,045 shares of the company's stock were exchanged, compared to its average volume of 98,300. The company has a quick ratio of 1.03, a current ratio of 1.34 and a debt-to-equity ratio of 1.07. Journey Medical has a 1-year low of $3.54 and a 1-year high of $8.25. The company's fifty day moving average price is $7.19 and its 200-day moving average price is $6.31. The firm has a market cap of $165.55 million, a PE ratio of -18.19 and a beta of 0.80.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Cetera Investment Advisers increased its holdings in shares of Journey Medical by 21.8% during the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company's stock valued at $54,000 after acquiring an additional 2,478 shares during the last quarter. Focus Partners Advisor Solutions LLC bought a new stake in shares of Journey Medical in the 2nd quarter worth approximately $72,000. Titleist Asset Management LLC lifted its position in shares of Journey Medical by 18.3% during the 1st quarter. Titleist Asset Management LLC now owns 12,900 shares of the company's stock worth $76,000 after buying an additional 2,000 shares during the period. Dimensional Fund Advisors LP bought a new position in shares of Journey Medical during the 4th quarter worth approximately $80,000. Finally, Kovitz Investment Group Partners LLC lifted its position in shares of Journey Medical by 112.9% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company's stock worth $97,000 after buying an additional 13,105 shares during the period. Institutional investors and hedge funds own 7.25% of the company's stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.